eosinophil survival
Recently Published Documents


TOTAL DOCUMENTS

115
(FIVE YEARS 1)

H-INDEX

31
(FIVE YEARS 1)

2019 ◽  
Vol 68 (2) ◽  
pp. 274-276 ◽  
Author(s):  
Yohei Maeda ◽  
Takeshi Tsuda ◽  
Yoshito Takeda ◽  
Shohei Koyama ◽  
Yoshitomo Hayama ◽  
...  

2018 ◽  
Vol 196 ◽  
pp. 68-73 ◽  
Author(s):  
Shigeharu Ueki ◽  
Junko Nishikawa ◽  
Mineyo Fukuchi ◽  
Yasunori Konno ◽  
Masahide Takeda ◽  
...  

2018 ◽  
Vol 96 (4) ◽  
pp. 426-438 ◽  
Author(s):  
Praveen Vimalathas ◽  
Alexandra Farris ◽  
Dorothea Letner ◽  
Vikram Deshpande ◽  
Vijay Yajnik ◽  
...  

2017 ◽  
Vol 104 (1) ◽  
pp. 21-29 ◽  
Author(s):  
Perri Rozenberg ◽  
Hadar Reichman ◽  
Itay Moshkovits ◽  
Ariel Munitz

Immunity ◽  
2016 ◽  
Vol 44 (4) ◽  
pp. 795-806 ◽  
Author(s):  
Stephen P. Matthews ◽  
Sarah J. McMillan ◽  
Jeff D. Colbert ◽  
Rachel A. Lawrence ◽  
Colin Watts
Keyword(s):  

2016 ◽  
Vol 124 (1) ◽  
pp. 109-120 ◽  
Author(s):  
Magda F. Serra ◽  
Josiane S. Neves ◽  
Gina C. Couto ◽  
Amanda C. Cotias ◽  
Camila R. Pão ◽  
...  

Abstract Background Inhaled lidocaine antagonized bronchospasm in animal models and patients, but adverse effects limited its efficacy. This study evaluated the antibronchospasm potential of the analog JM25-1, exploring in vitro mechanisms and translation to an animal model. Methods The effectiveness of JM25-1 was assessed in GH3 cells, rat tracheal rings, mouse lymphocytes, and human eosinophil systems in vitro, assessing changes in Na+ current, contraction, proliferation, and survival, respectively. Lung function and inflammatory changes were studied in ovalbumin-sensitized mice. Results The efficacy of JM25-1 was higher than lidocaine in inhibiting carbachol-induced and calcium-induced tracheal contractions (maximum effect inhibition at 1 mM [%]: 67 ± 10 [JM25-1] vs. 41 ± 11 [lidocaine] [P < 0.001] for carbachol; 100 ± 3 [JM25-1] vs. 36 ± 26 [lidocaine] [P < 0.001] for Ca2+; mean ± SD; n = 9 each) but lower in Na+ current (50% inhibitory concentration = 151.5, n = 8 vs. 0.2 mM; n = 5; P < 0.001). JM25-1 also inhibited eosinophil survival (dead cells [%]: 65 ± 6; n = 4; P < 0.001 at 1 mM) and lymphocyte proliferation (cells in phase S + G2 [%]: 94 ± 10; n = 6; P < 0.001) at 0.6 mM. Aerosolized JM25-1 (1%) decreased lung eosinophil numbers from 13.2 ± 2.4 to 1.7 ± 0.7 × 104/μm2 (n = 6; P < 0.001) and neutrophils from 1.9 ± 0.4 to 0.2 ± 0.1 × 104/μm2 (n = 7; P < 0.001). Other parameters, including airway hyperreactivity, cytokines, mucus, and extracellular matrix deposition, were also sensitive to aerosolized JM25-1. Conclusion These findings highlight the potential of JM25-1, emphasizing its putative value in drug development for clinical conditions where there is bronchospasm.


Blood ◽  
2015 ◽  
Vol 125 (25) ◽  
pp. 3896-3904 ◽  
Author(s):  
Christian Schwartz ◽  
Ralf Willebrand ◽  
Silke Huber ◽  
Rudolf A. Rupec ◽  
Davina Wu ◽  
...  

Key Points IL-3, IL-5, and GM-CSF promote eosinophil survival by NF-κB–induced upregulation of Bcl-xL, which can be blocked by specific inhibitors. Specific and constitutive deletion of the inhibitor of NF-κB (IκBα) in eosinophils in vivo reduced apoptosis during helminth infection.


Blood ◽  
2015 ◽  
Vol 125 (25) ◽  
pp. 3831-3832 ◽  
Author(s):  
Nives Zimmermann ◽  
Marc E. Rothenberg
Keyword(s):  

2015 ◽  
Vol 135 (2) ◽  
pp. AB221
Author(s):  
Xiang Zhu ◽  
Jeffrey D. Molkentin ◽  
Nives Zimmermann

Sign in / Sign up

Export Citation Format

Share Document